Published in Drug Week, January 7th, 2005
Data from the study were independently analyzed by the Montreal Heart Institute (MHI) under the direction of Jean-Claude Tardif, MD, principal investigator of CART-2, and by the Cleveland Clinic Foundation (CCF) under the direction of Steven Nissen, MD.
The primary endpoint of the trial was a change in coronary atherosclerosis, measured as total plaque volume after a 12-month treatment period compared to baseline values. Combined results of the final analysis from the two...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.